Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700204 | 0.91 | HRH3 (0.52) | HRH3SLC6A4GRM5 | |
| SCHEMBL3902848 | 0.88 | HRH3 (0.64) | HRH3 | |
| SCHEMBL3902370 | 0.86 | HRH3 (0.49) | HRH3SLC6A4 | |
| SCHEMBL3899860 | 0.80 | HRH3 (0.90) | HRH3SLC6A4 | |
| SCHEMBL3902790 | 0.76 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3902855 | 0.75 | HRH3 (0.98) | HRH3 | |
| SCHEMBL3899432 | 0.75 | HRH3 (0.80) | HRH3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3896501 | 0.75 | HRH3 (0.98) | HRH3 | |
| SCHEMBL3899144 | 0.74 | HRH3 (0.79) | HRH3 | |
| SCHEMBL3899776 | 0.74 | HRH3 (0.79) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482364-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482364-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7446104-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446104-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20080103135-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-05-01 | — | — | US | disclosed |
| US-20080103135-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-05-01 | — | — | US | disclosed |
| US-20080096876-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-04-24 | — | — | US | disclosed |
| US-20080096876-A1 | PHENYLALKYNES | APODACA RICHARD | 2008-04-24 | — | — | US | disclosed |
| US-7288540-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288540-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070072837-A1 | Phenylalkynes | APODACA RICHARD | 2007-03-29 | — | — | US | disclosed |
| US-20070072837-A1 | Phenylalkynes | APODACA RICHARD | 2007-03-29 | — | — | US | disclosed |
| US-20060258859-A1 | Phenylalkynes | APODACA RICHARD | 2006-11-16 | — | — | US | disclosed |
| EP-1567494-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6884803-B2 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1451167-A1 | PHENYLALKYNES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004050623-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103135-A1 | PHENYLALKYNES | HRH2, HRH3, HNMT | HRH3 2/4885SLC6A4 1010/4885GRM5 1417/4885 |
| US-20060258859-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HRH3 2/4885SLC6A4 1010/4885GRM5 1417/4885 |
| US-20070072837-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HRH3 2/4885SLC6A4 1010/4885GRM5 1417/4885 |
| US-20080096876-A1 | PHENYLALKYNES | HRH2, HRH3, HNMT | HRH3 2/4885SLC6A4 1010/4885GRM5 1417/4885 |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | HRH3, HRH2, HRH4 | HRH3 1/4885SLC6A4 307/4885GRM5 71/4885 |
| US-20040002604-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HRH3 2/4885SLC6A4 1010/4885GRM5 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.